Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors

Cancer Research

Volumn 65, Issue 7, 2005, Pages 2755-2760

  Dasgupta, Biplab ^a   Yi, Yijun ^a   Chen, David Y ^a   Weber, Jason D ^a   Gutmann, David H ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Box 8111 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3 KINASE; S6 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASTROCYTE; BIOGENESIS; BRAIN TUMOR; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; MOUSE; MOUSE MUTANT; NEUROFIBROMATOSIS; NONHUMAN; OPTIC NERVE GLIOMA; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEOMICS; RIBOSOME; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ASTROCYTES; BRAIN NEOPLASMS; GENES, NEUROFIBROMATOSIS 1; GLIOMA; HUMANS; MICE; MICE, TRANSGENIC; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; PROTEIN KINASES; PROTEOMICS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 16844375160     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4058     Document Type: Article

References (43)

1. Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999;89:1-6.
2. Listernick R, Charrow J, Greenwald MJ, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994;125:63-6.
3. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-25.
4. Xu GF, O'Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990;62:599-608.
5. Bollag G, McCormick F. GTPase activating proteins. Semin Cancer Biol 1992;3:199-208.
6. Guha A, Lau N, Huvar I, et al. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 1996;12:507-13.
7. Lau N, Feldkamp MM, Roncari L, et al. Loss of neurofibromin is associated with activation of Ras/MAPK and PI3K/AKT signalling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 2000;59:759-67.
8. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996;12:144-8.
9. Sherman LS, Atit R, Rosenbaum T, Cox AD, Ratner N. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J Biol Chem 2000;275:30740-5.
10. Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW. Neurofibromin GTPase-activating protein-related domains restore normal growth in NF1-/- cells. J Biol Chem 2001;276:7240-5.
11. Li Y, White R. Suppression of a human colon cancer cell line by introduction of an exogenous NF1 gene. Cancer Res 1996;56:2872-6.
12. Fieber LA, Gonzalez DM, Wallace MR, Muir D. Delayed rectifier K currents in NF1 Schwann cells. Pharmacological block inhibits proliferation. Neurobiol Dis 2003;13:136-46.
13. Kim HA, Ling B, Ratner N. Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol Cell Biol 1997;17:862-72.
14. Packer RJ, Gutmann DH, Rubenstein A, et al. Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology 2000;58:1461-70.
15. Dasgupta B, Li W, Perry A, Gutmann D. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res 2005;65:236-45.
16. Dasgupta B, Dugan LL, Gutmann DH. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci 2003;23:8949-54.
17. Tong J, Hannan F, Zhu Y, Bernards A, Zhong Y. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat Neurosci 2002;5:95-6.
18. Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol 2002;22:5100-13.
19. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001;15:3243-8.
20. Walsh AB, Bar-Sagi D. Differential activation of the Rac pathway by Ha-Ras and K-Ras. J Biol Chem 2001;276:15609-15.
21. Chen Z, Otto JC, Bergo MO, Young SG, Casey PJ. The C-terminal polylysine region and methylation of K-ras are critical for the interaction between K-ras and microtubules. J Biol Chem 2000;275:41251-7.
22. Uhlmann EJ, Li W, Scheidenhelm DK, Gau CL, Tamanoi F, Gutmann DH. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia 2004;47:180-8.
23. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.
24. Lewis TS, Hunt JB, Aveline LD, et al. Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry. Mol Cell 2000;6:1343-54.
25. Okuda M, Horn HF, Tarapore P, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000;103:127-40.
26. Itahana K, Bhat KP, Jin A, et al. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 2003;12:1151-64.
27. Turck N, Richert S, Gendry P, et al. Proteomic analysis of nuclear proteins from proliferative and differentiated human colonic intestinal epithelial cells. Proteomics 2004;4:93-105.
28. Brady SN, Yu Y, Maggi LB Jr, Weber JD. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol Cell Biol 2004;24:9327-38.
29. Anand N, Murthy S, Amann G, et al. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 2002;31:301-5.
30. Eberle J, Fecker LF, Bittner JU, Orfanos CE, Geilen CC. Decreased proliferation of human melanoma cell lines caused by antisense RNA against translation factor eIF-4A1. Br J Cancer 2002;86:1957-62.
31. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, Holland EC. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 2003;12:889-901.
32. Montagne J, Stewart MJ, Stocker H, Hafen E, Kozma SC, Thomas G. Drosophila S6 kinase: a regulator of cell size. Science 1999;285:2126-9.
33. Radimerski T, Montagne J, Rintelen F, et al. dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1. Nat Cell Biol 2002;4:251-5.
34. Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994;370:527-32.
35. Donovan S, See W, Bonifas J, Stokoe D, Shannon KM. Hyperactivation of protein kinase B and Erk have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer Cell 2002;2:507-14.
36. Chung J, Grammer TC, Lemon KP, Kazlauskas A, Blenis J. PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994;370:71-5.
37. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807-26.
38. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr, Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 1996;15:5256-67.
39. Shao J, Evers BM, Sheng H. Roles of phosphatidylinositol 3′-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 2004;64:229-35.
40. Bajenaru ML, Hernandez MR, Perry A, et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 2003;63:8573-7.
41. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002;62:6141-5.
42. Albanell J, Codony-Servat J, Rojo F, et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001;61:6500-10.
43. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 2002;3:295-304.